The aim of the present study was to examine whether either the PTPN22 gene or genotypes of the HLA–DRB1 gene, which are associated with disease severity, are predictors of all-cause and CVD mortality in patients with IP or RA and whether any effect is independent of autoantibody status. This evidence concerns the gene PTPN22 and rheumatoid arthritis.